Tumor Necrosis Factor- Regulates Hematopoietic Stem Cell Activation

2018 ◽  
Vol 64 ◽  
pp. S99
Author(s):  
Alexandra Rundberg Nilsson ◽  
David Bryder ◽  
Cornelis Pronk
Keyword(s):  
Stem Cell ◽  
Tumor Necrosis Factor ◽  
Hematopoietic Stem Cell ◽  
Tumor Necrosis ◽  
Cell Activation ◽  
Hematopoietic Stem ◽  
Necrosis Factor

scholarly journals The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

Blood ◽  
2008 ◽  
Vol 112 (8) ◽  
pp. 3073-3081 ◽  
Author(s):  
Gregory A. Yanik ◽  
Vincent T. Ho ◽  
John E. Levine ◽  
Eric S. White ◽  
Thomas Braun ◽  
...  
Keyword(s):  
Stem Cell ◽  
Tumor Necrosis Factor ◽  
Hematopoietic Stem Cell Transplantation ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Complete Response ◽  
Hematopoietic Stem ◽  
Idiopathic Pneumonia Syndrome ◽  
Factor Α ◽  
Necrosis Factor

Abstract Idiopathic pneumonia syndrome (IPS) refers to a diffuse, noninfectious, acute lung injury after hematopoietic stem cell transplantation. Historically, IPS is associated with respiratory failure and mortality rates exceeding 50%. Preclinical studies have implicated tumor necrosis factor-α as an important effector molecule in the development of disease. We studied the tumor necrosis factor-α inhibitor, etanercept, combined with corticosteroids in treating 15 patients (median age, 18 years; range, 1-60 years) with IPS. Eight of 15 patients required mechanical ventilation at therapy onset. Etanercept was administered subcutaneously at a dose of 0.4 mg/kg (maximum 25 mg) twice weekly, for a maximum of 8 doses. Therapy was well tolerated with no infectious pulmonary complications noted. Ten of 15 patients had a complete response, defined as the ability to discontinue supplemental oxygen support during study therapy. The median time to complete response was 7 days (range, 3-18 days), with a day 28 survival of 73%. IPS onset was associated with elevations of several inflammatory proteins in the bronchoalveolar lavage fluid and plasma, and response to therapy correlated with reductions in pulmonary and systemic inflammation. The combination of etanercept and corticosteroids is safe and is associated with high response rates and improved survival in patients with IPS.

Sign in / Sign up

Export Citation Format

Share Document